Sunday, November 8, 2026

USD/CNH Went Down By Over 1% In The Last 10 Sessions

ViaNews Editorial Team

February 4, 2024

USD/CNH Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.59% for the last 10 sessions. At 14:06 EST on Sunday, 4 February, USD/CNH (USDCNH) is $7.21.

USD/CNH's yearly highs and lows, it's 0.046% up from its 52-week low and 0% down from its 52-week high.

News about

  • Eur/usd price analysis: advances to near 1.0870 followed by barrier around 21-day EMA. According to FXStreet on Friday, 2 February, "The EUR/USD pair could find the immediate resistance zone around the 21-day Exponential Moving Average (EMA) at 1.0882 followed by the psychological level at 1.0900.", "Traders could wait for the MACD confirmation before making aggressive bets in the EUR/USD pair."
  • Eur/usd extends gains towards 1.0900 as traders brace for NFP. According to FXStreet on Friday, 2 February, "The EUR/USD pair extends its gains for the second consecutive day, edging higher to near 1.0880 during the European session on Friday. ", "A break below this region could push the EUR/USD pair to approach the psychological support at 1.0800, followed by the weekly low at 1.0779."
  • Eur/usd: unlikely to see an immediate return to the area above 1.0900 – commerzbank. According to FXStreet on Friday, 2 February, "I would therefore be critical of an immediate return of EUR/USD to the area above 1.0900."
  • Eur/usd dips toward 1.0800 on hot US nonfarm payrolls, strong US dollar. According to FXStreet on Friday, 2 February, "From a technical perspective, the EUR/USD breaching of the 200-day moving average (DMA) could open the door for further downside. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com